Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy (Adv. Sci. 40/2024)

Nanovaccine In article number 2404159, Helena F. Florindo, Ronit Satchi‐Fainaro, and co‐workers describe the development of a next‐generation thermostable multi‐epitope mannosylated nanovaccine administered intranasally. This innovative nanovaccine generates mucosal immunity while regulating PD‐1/PD‐L1 axis within the DC‐T cell interface, coordinating CD4 and CD8 T‐cell immunities and activating robust neutralizing antibody responses against SARS‐CoV‐2. This cover artwork highlights the main features of our novel delivery system: The sugar‐coated train carries the SARS‐CoV‐2 peptides cargo, while speeding on PD‐L1 siRNA tracks through the nose caves to reach the final destination‐ an effector and protective immunity. Illustration credit: Sharon Amlani. [Image: see text]

Authors

Publication Details

Journal
Advanced Science
Published
2024-10-01
DOI
https://doi.org/10.1002/advs.202470245
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy (Adv. Sci. 40/2024)

Michael Mor, Mira Toister‐Achituv, Yulia Liubomirski, Sarit Aviel‐Ronen et al.
1 links
Advanced Science
Nanoplatforms for cancer theranostics
article

Intranasal Multiepitope PD‐L1‐siRNA‐Based Nanovaccine: The Next‐Gen COVID‐19 Immunotherapy (Adv. Sci. 40/2024)

Michael Mor, Mira Toister‐Achituv, Yulia Liubomirski, Sarit Aviel‐Ronen, Daniella Vaskovich‐Koubi, Ana Zarubica, Rita C. Acúrcio, Natalia T. Freund, Manon Fabregue, Bárbara Carreira, Carlos Araújo, Ronit Satchi‐Fainaro, Ana S. Viana, Eilam Yeini, Cárol Palma, João Gonçalves, Vera Ferreira, Helena F. Florindo, Adva Yeheskel, Ron Kleiner, Eran Bacharach, Solene Matthieu, Capucine Guerry
article en

Abstract

Nanovaccine In article number 2404159, Helena F. Florindo, Ronit Satchi‐Fainaro, and co‐workers describe the development of a next‐generation thermostable multi‐epitope mannosylated nanovaccine administered intranasally. This innovative nanovaccine generates mucosal immunity while regulating PD‐1/PD‐L1 axis within the DC‐T cell interface, coordinating CD4 and CD8 T‐cell immunities and activating robust neutralizing antibody responses against SARS‐CoV‐2. This cover artwork highlights the main features of our novel delivery system: The sugar‐coated train carries the SARS‐CoV‐2 peptides cargo, while speeding on PD‐L1 siRNA tracks through the nose caves to reach the final destination‐ an effector and protective immunity. Illustration credit: Sharon Amlani. [Image: see text]

Advanced ScienceVol. 11(40)
Openalex Percentile: Top 83%
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.